Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q)

13 Jun 2017

Abstract excerpt

Abstract Deletion of the chromosome 5q [del(5q)] is one of the most common cytogenetic abnormalities observed in patients with de novo myelodysplastic syndromes (MDS) and therapy-related MDS or acute myeloid leukemia (t-MDS/tAML). Emerging evidence indicates that activation of the Wnt/β-catenin pathway contributes to the development of myeloid neoplasms with del(5q). Whether β-catenin is a potential therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer-related gene regulation
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28611040
DOI: 10.1158/0008-5472.can-17-0202

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q)PMID 28611040Read ↗

Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasmsSemantic proximity Read ↗

Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in miceSemantic proximity Read ↗

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesSemantic proximity Read ↗

Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.Semantic proximity Read ↗

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Semantic proximity Read ↗

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.Semantic proximity Read ↗

Cytotoxic Therapy–Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid NeoplasmsSemantic proximity Read ↗

Molecular dissection of the 5q deletion in myelodysplastic syndrome.Semantic proximity Read ↗

RECENT ADVANCES IN THE 5Q- SYNDROMESemantic proximity Read ↗

A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.Semantic proximity Read ↗

Haploinsufficiency of Apc leads to ineffective hematopoiesisSemantic proximity Read ↗

Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.